Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mizoribine after cyclosporine in children with frequently relapsing nephrotic syndrome
jRCTs051200070Completed
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mizoribine in nephrosis. Primary endpoint: Primary: Rate of regression to treatment failure up to 52 weeks after starting cyclosporine tapering. Started Dec 2020; status: completed.
02
Drugs
mizoribine
03
Conditions
nephrosis
Beyond the preview
Go deeper on jRCTs051200070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200070.